Get Support

Learn Mode

UTHR - United Therapeutics Corp

201

$588.36

$65.53 (12.534%)

At market close

$587.17

-$1.19 (-0.202%)

After Hours 3/30/26, 11:46 PM

3.58/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

UTHR

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$25.79B

Industry

Biotechnology

EPS (TTM)

$28.21

P/E (TTM)

19.32

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

8.10

P/B

3.63

Diluted Shares

47.30M

Ex-Dividend

--

Next Earnings

04-28

Forward P/E

20.12

Payout Ratio

--

P/FCF (TTM)

24.91

FCF Yield

4.01%

Earnings Yield

5.18%

52 Week Range

Score Card

Explore Scores Tab

3.58

Good

United Therapeutics Corp has grown revenue at 10.61% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

3.00

Average

Growth

2.00

Bad

Profitability

1.00

Very Bad

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

12 new filings were in the last 7 days

Filter Form Types

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-30 17:30:08

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-30 07:00:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-27 16:32:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-27 16:31:39

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:53:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-26 16:34:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-26 16:34:42

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-26 16:04:36

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-25 16:31:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:33:33

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:32:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:31:46

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$740.25

25.8%

Avg:

$603.09

2.5%

Low:

$470.66

-20.0%

(% change is relative to the current stock price: $588.36)

Analyst Recommendations

Go to Analyst Tab

4.10

Good

33%

Strong Buy (7)

43%

Buy (9)

24%

Hold (5)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.unither.com/
Address
1000 Spring St, Silver Spring MARYLAND, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1082554

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

IPO Date

1999-06-17

Industry

Biotechnology

Total Employees

1,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences